October 24, 2025

Elinzanetant Approved for Menopausal Hot Flashes by FDA

Bayer’s dual neurokinin 1 and 3 receptor antagonist elinzanetant (Lynkuet) reduced the frequency and severity of menopausal vasomotor symptoms in phase 3 OASIS trials, providing a once daily, nonhormonal treatment option for moderate to severe hot flashes.

Conexiant

October 23, 2025

Is the Estradiol Ring Losing Strength Early?

Patients reported return of vasomotor symptoms before the 3-month mark in real-world use. 

Conexiant

October 14, 2025

Breast Screening: The Age Question

Screening every two years offers greater life-year gains in breast cancer care.

Conexiant

September 30, 2025

Long COVID &  Periods: What's the Link?

Researchers examine menstrual changes and immune patterns in patients with long COVID.

Conexiant

September 26, 2025

Age 80 and Beyond: The Screening Debate

How mammography after age 80 affects breast cancer stage at diagnosis and survival.

Conexiant

January 16, 2025

Algorithm Improves Diagnosis of Uterine Lesions

"The preoperative 3-class diagnostic algorithm and risk class system can stratify women according to risk of malignancy."

Conexiant

October 28, 2024

Single Swab Approach Assesses Co-Occurring Vaginal Infections

A recent study reveals that 80% of women with STIs may have bacterial vaginosis, highlighting the potential benefits of simultaneous STI and vaginitis testing in clinical practice.

Conexiant

November 14, 2024

Can Botox Ease Chronic Pelvic Pain?

A recent study assessed the efficacy of Botulinum Toxin A injections in conjunction with pelvic floor muscle therapy for women with chronic pelvic pain, revealing interesting insights into its effectiveness compared to a placebo.

Conexiant

December 10, 2024

Hormone Therapy Risks Vary: Tibolone Linked to Arterial Events

Recent study links tibolone use in menopausal hormone therapy to a 52% increased cardiovascular disease risk, emphasizing the need for tailored hormone therapy approaches and further research in BMJ.

Conexiant